Correlates of public support toward federal funding for harm reduction strategies by unknown
Kulesza et al. Substance Abuse Treatment, Prevention, and Policy  (2015) 10:25 
DOI 10.1186/s13011-015-0022-5RESEARCH Open AccessCorrelates of public support toward federal
funding for harm reduction strategies
Magdalena Kulesza1,2*, Bethany A. Teachman3, Alexandra J. Werntz3, Melissa L. Gasser1 and Kristen P. Lindgren1Abstract
Background: Historically, US federal policy has not supported harm reduction interventions, such as safe injection
facilities (SIFs) and needle and syringe programs (NSPs), which can reduce the burden associated with injection
drug use. Given recent increases in abuse of both legal and illegal opioids, there has been a renewed debate about
effective ways to address this problem. The current study (1) assessed participants’ support for SIFs and NSPs, and
(2) evaluated several demographic factors (e.g., age, gender, race, education, political ideology, and religiosity) and
individual differences in stigmatizing beliefs about people who inject drugs (PWID) that might relate to support for
these interventions.
Methods: U.S. adults (N = 899) completed a web-based study that assessed self-reported support for NSPs and SIFs,
and stigma about PWID.
Results: The majority of participants were at least somewhat supportive of both NSPs and SIFs. Regression analyses
indicated greater support for NSPs and SIFs was predicted by more liberal political ideology, more agreement that
PWID deserve help rather than punishment, older age, and male gender. Also, participants who endorsed lower
stigma about PWID were more supportive of NSPs and SIFs. Race, religiosity, and education did not predict support
for NSPs and SIFs.
Conclusions: Most participants tended to report support for harm reduction strategies. Age, political ideology, and
individual differences in stigmatizing beliefs about PWID were significantly associated with support. Given the
potential malleability of stigmatizing beliefs, efforts that seek to shift stigma about PWID could have important
implications for public policy towards harm reduction strategies for PWID.
Keywords: Public stigma, Intravenous drug use, Harm reduction, Safe injection facilities, Needle and syringe
programsBackground
Injection drug use is associated with significant societal
costs, and both opiate use and related deaths are increas-
ing nationwide [5]. Although harm reduction strategies,
such as needle and syringe programs (NSPs) and safe in-
jection facilities (SIFs), have been shown to be effective at
reducing negative consequences of drug use [23, 41, 42],
these strategies are not currently part of federal drug con-
trol policy in the U.S., likely due to political, legal, and
moral objections [1, 35], as well as stigma, and perception
of drug use as a criminal behavior, rather than a health* Correspondence: mkulesza@rand.org
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creativecommons.org/publicdomain/zero/1.0/problem [33]. Still, a number of U.S. states provide fund-
ing for some form of harm reduction interventions, and
there is renewed debate about the most effective strategies
to address the burden of opiate addiction, and injection
drug use [31]. Given the significant impact of public opin-
ion on policy decisions [4], it is crucial to gain a better un-
derstanding of attitudes toward harm reduction policies
held by the individuals in the U.S. While previous public
opinion polls have contributed to our knowledge, they
have tended to look at attitudes on average, rather than
considering individual differences in support for harm re-
duction strategies [40]. Thus, the goal of the current study
was to evaluate several demographic factors and individual
differences in beliefs that might differentially predict sup-
port for NSPs and SIFs.rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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the U.S. in spite of data supporting their efficacy in re-
ducing harm among PWID [41, 42]. Our interest in SIFs
was motivated by two reasons. First, there is accumulat-
ing research support for their efficacy in reducing high
risk behaviors while increasing healthcare participation
among PWID [24, 43, 44]. Second, to our knowledge,
U.S. adults’ support for SIFs has not been evaluated.
NSPs refer to the provision of sterile injection equipment
to PWID to reduce transmission of infectious disease
[18, 20], whereas SIFs refer to locales where PWID can
more safely (i.e., supervised by a nurse or social worker)
consume drugs. There is robust support for NSPs efficacy
in reducing the transmission of HIV without increasing
drug use [35, 41, 42]. While NSPs have a longer history
and more scientific scrutiny, SIFs have received increased
attention from researchers in recent years. SIFs were
established to reduce risk of overdose, infectious disease
transmission, and negative impact on public order [2, 17].
A growing body of research indicates that SIFs reduce
high-risk behaviors among PWID, such as syringe sharing
[16, 21, 22, 24, 44], while facilitating provision of health
care and addiction treatment [14, 38] without increasing
drug use or injecting behavior [23, 25, 43].
In contrast to the lack of data about SIFs in the U.S.,
there are some data describing support towards NSPs.
Specifically, a systematic analysis of national public opin-
ion polls evaluating support towards NSPs indicated
that, depending on the poll, between 29 and 66 % of in-
dividuals endorsed favorable views [40]. These statistics
represent quite a wide range of support, and the authors
suggested several reasons for the variability [40]. First, it
might be partially due to how the survey questions are
worded, such as the use of loaded terms like “drug addicts’
or “junkies,” that could contribute to more bias-driven
responses. In fact, the authors documented that simply
replacing “those addicted to illegal drugs” with “drug
addicts” was related to a 9 % drop in support towards
NSPs. Hence, the authors recommended avoiding pe-
jorative terms in survey questions. Second, they identi-
fied the beliefs and/or bias of an organization as a
potential explanatory factor. Given that polls sponsored
by more liberal organizations reported more support
towards NSPs than those sponsored by more conserva-
tive organizations, the authors recommended that polls
should be sponsored by organizations without a public
position on the issue. Third, the lack of knowledge
about the scientific evidence supporting efficacy of
these strategies in reducing HIV infection may be an-
other reason for the inconsistent findings and low
support. Last, the authors noted the importance of
evaluating factors that might influence public support
toward harm reduction strategies; the focus of the
current study.We are not aware of any published research that dir-
ectly assesses predictors of public support for harm re-
duction services in the US. When considering plausible
candidates, U.S. and international research related to
other drug policies is informative. First, stigma toward
individuals coping with substance abuse is one possible
factor; here, we focus on public stigma, which is the en-
dorsement of negative stereotypes by society at large,
which can then lead to negative emotional reactions
(e.g., anger, fear) and discrimination toward individuals
belonging to the stigmatized group [10]. Given stigma
relates to a preference for more punitive, rather than
help-related, responses to individuals with substance
abuse [26, 28, 33], it is expected that greater stigma will
predict rejection of harm reduction approaches in the
current study.
Second, findings from two studies conducted in
Canada assessing participants’ views about harm reduc-
tion programs indicated that several factors were associ-
ated with greater support: higher income and education
[13, 39], younger age [39], personal use of cocaine or
marijuana in the past year [13], favorable view of
marijuana decriminalization [13], and perception of indi-
viduals with substance abuse as ill people [13]. Gender,
however, was not a significant predictor in one study
[13] while another reported that women were more sup-
portive [39]. Also, a study evaluating U.S. public support
for increased government spending for “dealing with
drug addiction” found that while all demographic groups
were generally supportive of increased spending, after
controlling for general domestic spending, men (vs.
women), conservatives (vs. liberals), older (vs. younger)
individuals, and residents of the South (vs. North) were
more supportive of spending [32]. These surprising re-
sults were speculated to stem from participants’ as-
suming that drug-problem spending would be more
punitive/criminal justice-based, rather than public
health-oriented. Interestingly, race/ethnicity was not a
significant predictor. Because these data were either
from Canada [13, 39] or are dated [32], we evaluated
predictors of current support toward harm reduction
services in a large U.S. sample.
Overview
We sought to add to the literature in the following ways.
First, evidence suggests that even after accounting for
other factors such as the influence of interest groups,
public opinion has a significant impact on public policy
[4]. Hence, by evaluating public views towards provision
of federal funding for harm reduction strategies, we in-
crease our knowledge about a potential source of the
current U.S. federal ban on support for harm reduction
strategies. Second, we addressed some of the criticisms
of the extant literature [40] by avoiding use of prejudicial
Table 1 Study participant characteristics (n = 899)
Gender (% women) 62.4
Age (M, SD, range) 38.97 (13.65, 19–90)
Ethnicity (%)
Hispanic or Latino 7.3
Not Hispanic or Latino 79.5
Unknown or did not report 13.2
Race (%)
Caucasian 69.9
Black or African American 13.2
More than one race 7.3
Asian 4.2
Other or unknown 3.1
American Indian or Alaskan Native .7
Native Hawaiian or other Pacific Islander .7
Did not report race .9
Education (%)
Less than a high school degree 1.4
High school degree, some college, or an
Associate’s degree
39.2
Bachelor’s degree or some graduate school 28.1
Advanced degree (e.g., PhD, MD) 30.4









Did not report 4.1
Religiosity (%)
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ing PWID in behavioral terms, and linking the use of
harm reduction strategies to scientific evidence. Third,
given the dearth of research looking at correlates of U.S.
public opinion toward government funding for harm re-
duction services, we also assessed whether public stigma
toward PWID and a series of demographic factors were
related to the extent of support. Note, we are not attempt-
ing to conduct an epidemiological study among a repre-
sentative sample; rather, to identify promising predictors.
We used a sample that was relatively diverse and large
enough to enable analyses of various individual differ-
ences, but we make no claims that the sample is represen-
tative. Finally, we are the first to assess support toward
SIFs among U.S. adults.
Our aims, therefore, were to: (1) assess participants’
opinions about providing government funding for SIFs
and NSPs, and (2) evaluate several demographic and in-
dividual difference factors (age, gender, race, education,
political ideology, religiosity, and public stigma towards
PWID) that might relate to support for these strategies.
Methods
Participants
Participants were 899 volunteers at the Project Implicit
research website (https://implicit.harvard.edu/implicit/)
between July 24, 2013 and August 19, 2013. Out of 1453
individuals randomly assigned to this study, 1157 con-
sented to participate, and of those, 899 individuals com-
pleted study procedures and materials presented in this
manuscript. There were no significant differences on
demographic variables between study completers and
non-completers.
Project Implicit is a nonprofit website that investigates
attitudes and beliefs that are relatively outside of con-
scious control. Individuals are randomly assigned to
study topics after registering on the site and agreeing to
participate in a study. Only individuals over 18, fluent in
English, and citizens of the U.S. were eligible for the
present study; 98.3 % were current residents of the U.S.
Project Implicit samples are relatively diverse, and there
is evidence supporting the validity of Project Implicit’s
approach to web-based data collection [29, 30]. Partici-
pants are volunteers and are not compensated for study
participation. Volunteers find the website through a var-
iety of sources, such as surfing the web, an assignment for




To assess endorsement of NSPs, participants rated
agreement with the statement: “Federal funds should be
made available for needle/syringe exchange programs ifit can be shown that they reduce the transmission of
HIV among users and do not encourage the use of illegal
drugs.” Similarly, to assess endorsement of SIFs, partici-
pants rated agreement with the statement: “Supervised
injection facilities for current intravenous drug users
(i.e., legally sanctioned and medically supervised facilities
to consume drugs) should be made available through
federal funds if it can be shown that they reduce over-
dose deaths or infectious disease among users.” Both
items were rated on a four-point scale (1 = strongly
Table 2 Descriptive statistics for each candidate variable and
correlations with support toward NEPs and SIFs (n = 899)
Variable 1 2 M SD
1. NSPs policya – 3.29 .93
2. SIFs policya .53*** – 2.69 1.07
3. Pol. Ideologyb .41*** .38*** .87 1.66
4. Gender −.06 −.05
5. Age .15*** .16*** 38.97 13.65
6. Race −.09* −.00
7. Education .22*** .15***
7. PDSc −.34*** −.27*** 3.62 .93
8. SDSd −.26*** −.28*** 3.08 .53
9. Help/punishmente −.38*** −.31*** 2.39 1.61
10. Religiosity −.21*** −.17*** 2.06 1.02
aNSPs and SIFs policy = policy question assessing participants’ support toward
allocating government funds to Needle and Syringe Programs (NSPs) and Safe
Injection Facilities (SIFs), respectively. bPol. Ideology = political ideology.
cPDS = Perceived Dangerousness Scale. dSDS = Social Distance Scale.
eHelp/punishment = semantic differential question assessing participants’
view whether IDUs need help vs. punishment. Gender was coded as 0 = men
and 1 = women. Also, given that majority of our participants identified as
White or Caucasian (69.9 %) we recoded our Race variable to: 0 = White and
1 = everyone else. *p < .05, **p < .01, ***p < .001
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adapted from previous work examining public opinion
concerning SIFs [13].
Public stigma
The Social Distance Scale [27], an instrument assessing
attitudes towards interacting with someone with mental
illness, was adapted for the current study. All seven items
(e.g., “How would you feel about renting a room to a
former mental patient?”) were retained in the current
study; however, each was modified to reference PWID
instead of a “former mental patient.” Participants rated
each of the seven items on a four-point scale (1 = definitely
willing to 4 = definitely unwilling to), with higher scores
corresponding to greater desire for social distance.
Cronbach’s alpha in the current sample was .83, and
the scale has adequate psychometric properties when
modified for individuals coping with substance use-
related problems [3].
The Perceived Dangerousness Scale [27], an instrument
developed to assess beliefs about potential dangerousness
of individuals coping with mental illness, was modified to
assess perceived dangerousness of PWID. Five of the
original eight items (e.g., “One important thing about
former mental patients is that you cannot tell what they
will do from one minute to the next.”) were retained
and modified for the current study such that “former
mental patient” was replaced to reference PWID in-
stead. Response options to each of the five items were
on a six-point scale (1 = strongly disagree to 6 = strongly
agree). Higher scores correspond to greater stigma.
Cronbach’s alpha in the current sample was .71.
Help-punishment differential
To assess individuals’ self-reported support for helping
or punishing PWID, participants were asked to indicate
their inclination towards helping vs. punishing PWID.
Response to this single item measure used a nine-point
scale (1 = extremely deserving of help to 9 = extremely de-
serving of punishment) with higher scores indicating
greater endorsement of punishing PWID.
Demographic information
Participants reported gender, birthdate, race, ethnicity,
education level, religiosity, and political ideology. Both
religiosity and political ideology were assessed using
anchored four-point and seven-point Likert Scales re-
spectively. Thus, both variables were entered into the
regression analyses as-is. In addition, we asked participants
to select the highest level of education they completed
from the list of 14 categories. To simplify the analytic
approach and make the variable easier to interpret,
these categories were collapsed to four more general
categories shown in Table 1. Lastly, this variable wastreated as an ordinal variable and used in regression
analyses as-is. See Table 1 for response options and
frequencies.
Procedure
The current study was approved by the University of
Virginia’s Institutional Review Board for Social and Be-
havioral Sciences. Following random assignment to the
present study at the Project Implicit site, participants
read the informed consent agreement before beginning
the study. After participants completed all question-
naires assigned in random order, they were debriefed on
the purpose of the study.
Analytic strategy
Given that our key outcome variables (i.e., support for
NEPs and SIFs) were continuous and normally distributed,
separate linear regression models were used to evaluate
the predictors. For each model, all variables were entered
simultaneously given there was insufficient rationale to
suggest that any set of predictors ought to be evaluated
separately in stepwise regression. SPSS software was used
for all analytical procedures.
Results
See Table 2 for descriptive statistics for each candidate
variable. The majority of participants were supportive of
both NSPs and SIFs. More than 81 % either “somewhat”
or “strongly” agreed with funding NSPs, and more than
60 % either “somewhat” or “strongly” agreed with funding
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SIFs, t (765) = 17.02, p < .001.
Regarding support toward NSPs (see Table 3), the over-
all regression model was significant and accounted for
30 % of the variance in support for NSPs, F (9, 610) =
29.64, p < .001. Consistent with predictions, older age,
more liberal political ideology, lower perceptions that
PWID are dangerous, and stronger belief that PWID
deserve help rather than punishment were all positively
associated with support. While we did not propose specific
directional relationships for gender, race, education, and
religiosity, we found that male gender was significantly as-
sociated with higher support toward NSPs. However, race,
religiosity, and education were not significantly related to
support for NSPs. Last, contrary to expectation, desire for
distance from PWID was not a significant predictor. Polit-
ical ideology and beliefs about punishment/help for PWID
were the strongest predictors with medium effect sizes.
Age, gender, and beliefs about the dangerousness of PWID
were significant predictors, but their effect sizes were
small.Table 3 Regression Models Predicting Support toward
Needle and Syringe Programs (NSPs) and Safe Injection
Facilities (SIFs), n = 899
Standardized B SE B t Cohen’s d
Support Toward NSPs
Gender −0.09** 0.07 −2.62 0.21
Age 0.12** 0.01 3.47 0.28
Race −0.06 0.07 −1.76 0.14
Education 0.07 0.03 1.97 0.16
Political Ideology 0.24*** 0.02 6.15 0.49
Religiosity −0.07 0.03 −1.76 0.14
SDS −0.03 0.07 −0.78 0.06
PDS −0.15*** 0.04 −3.75 0.31
Needs Punishment/Help −0.25*** 0.02 −6.61 0.53
Support Toward SIFs
Gender −0.08* 0.08 −2.28 0.18
Age 0.14*** 0.01 3.96 0.32
Race 0.03 0.09 0.73 0.06
Education 0.01 0.01 0.34 0.11
Political Ideology 0.25*** 0.03 5.99 0.48
Religiosity −0.07 0.04 −0.84 0.07
SDS −0.11* 0.09 −2.57 0.21
PDS −0.03 0.05 −1.84 0.15
Needs Punishment/Help −0.18*** 0.03 −4.53 0.37
Gender was dummy-coded (0 =men, 1 = women). Race was dummy-coded
(0 =White, 1 = everyone else). Cohen’s d = 2 t/ √df. SDS = Social Distance Scale.
PDS = Perceived Dangerousness Scale. Needs Help/Punishment = semantic
differential question assessing participants’ view whether IDUs need help vs.
punishment. *p < .05, **p < .01, ***p < .001Regarding support toward SIFs (see Table 3), the re-
gression model was significant and accounted for 24 %
of the variance, F (9, 610) =21.27, p < .001. As predicted,
more liberal political ideology, lower desire for distance
from PWID, and stronger belief that they deserve help
rather than punishment were all significantly related to
more support. Older age also predicted greater support,
and men reported stronger support for SIFs than
women. Contrary to expectation, perceived dangerous-
ness of PWID was not a significant predictor. Similarly,
religiosity, race, and education were not significant pre-
dictors. Last, both political ideology and beliefs about
PWID’s deservingness of punishment/help were the
strongest predictors of support toward SIFs and had
medium effect sizes. Age, gender, and desire for distance
from PWID had small effect sizes.
Discussion
The current study provided the first test in a U.S. sample
of reported support for allocating government funds for
both SIFs and NSPs if it could be shown they reduce
harmful consequences of injection drug use. Results,
which need to be considered in light of the non-
representative sample characteristics, suggested that
while the majority of the sample was at least “somewhat”
supportive of both of these services, they were signifi-
cantly more supportive of NSPs than SIFs, which may be
partially related to the sample’s limited familiarity with
SIFs. NSPs have become a symbol of harm reduction
services for PWID [15], and despite the U.S. federal ban
on harm reduction, numerous state and local governments
have implemented NSPs [15]. Thus, it is possible that our
participants have had greater exposure to NSPs compared
to SIFs. This conjecture is consistent with findings that
support for harm reduction tends to increase following
implementation of those strategies [19, 37, 45]. However,
there are also reports of increased public support towards
SIFs over the course of six years despite of lack of imple-
mentation [36].
In line with extant literature [13, 36], while the major-
ity of our sample supported SIFs and NSPs, the average
endorsement scores were neither strongly favorable nor
unfavorable, and there was considerable variability. Fur-
thermore, we found that political ideology emerged as
the strongest predictor of support toward both NSPs
and SIFs, while age and gender played a smaller role.
Consistent with the extant literature, more liberal polit-
ical ideology was significantly related to higher support
[13, 32]. Additionally, male gender and older age were
significant predictors of higher support toward both
NSPs and SIFs, but race and education were not. These
results are consistent with some prior literature suggesting
that male gender, but not race, is a significant predictor of
support for drug policy initiatives [32]. However, there are
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cation [13, 39] and age [39].
Clearly, we can only speculate about the reasons for the
mixed findings, but some of the discrepant findings across
studies might be due to methodological differences, such
as the populations sampled (i.e., U.S. vs. Canadian adults).
Also, our questions asked about attitudes towards provid-
ing government support for SIFs and NEPs vs. providing
such services without specifying the funding source [13]
or questions about general attitudes toward those services
[39]. Hence, given the current study’s more direct policy
focus, it is not altogether surprising that political ideology
emerged as a stronger predictor than age or gender. In
addition, it is possible that some individuals’ general
attitudes towards harm reduction programs might differ
from their specific attitudes towards providing govern-
ment funding for these programs - an interesting question
for future work.
Consistent with hypotheses, a stronger belief that
PWID deserve help rather than punishment was related
to more support toward both NSPs and SIFs. While pre-
liminary and specific to this sample, these results are
consistent with extant literature indicating relationships
between different forms of public stigma and drug policy
initiatives [13, 28, 32]. At the same time, lower percep-
tions of PWID as dangerous uniquely predicted more
support toward NSPs, but desire for distance did not,
while lower desire for distance from PWID uniquely pre-
dicted support toward SIFs, but perceived dangerousness
did not. This differential prediction is both surprising
and novel. To our knowledge, this is the first study to
evaluate both perceived dangerousness and need for
distance from PWID as unique predictors of support
for various drug policy initiatives. One reason for the
dissociation may simply be the overlap between the
predictors (r = .53), which may have made it difficult to
observe unique prediction by both variables when entered
simultaneously in the model. This interpretation is sup-
ported by results of secondary analyses we conducted,
indicating significant correlations between both stigma
variables and support toward both NSPs and SIFs when
examined independently. At the same time, we expect
that perceived dangerousness and desired social distance
will sometimes show variable relations with support for
different types of drug policy initiatives, an important
question to investigate in future research that evaluates a
wider array of policies.
Although these results require replication, our findings
related to public stigma have important implications for
those with an interest in changing drug policy. Unlike
demographic variables, public stigma can be shifted
through invention efforts, and such interventions could
be important not only for the general public but also for
policy makers. For example, to the extent policy makersendorse these stigmatizing beliefs about PWID, it may
partly explain the lack of federal support for harm reduc-
tion. This idea is consistent with the Resource Allocation
Model [34], which suggests that perceptions of blame/
responsibility directed towards those who need govern-
ment resources are one factor that determines resource
allocation decisions. This issue is not simply academic
given robust evidence that individuals coping with sub-
stance abuse are viewed as personally responsible for their
problems and deserving of punishment [7, 11, 12].
Thus, it may be important in education and intervention
efforts to acknowledge and underscore the public stigma
towards PWID (and individuals coping with substance use
problems, more broadly). While we are not aware of any
interventions targeting public stigma towards PWID, it
may be possible to draw from the broader research on in-
terventions designed to reduce stigma towards individuals
with severe mental illness [6, 8, 9] and apply that to
PWID. Specifically, there is support for both education
(e.g., providing information about symptoms of mental
illness or prevalence of different disorders) and contact
strategies (e.g., making a personal connection between
stigmatized individuals and members of the general
public) in reducing stigma, with more robust support
towards the latter [6, 9]. Our results, if replicated, raise
the possibility that targeting perceptions of PWID as
deserving help versus punishment could have a sub-
stantial impact on support toward strategies designed
to help them, though this possibility needs to be tested
using experimental rather than correlational methods.
This may have impact at both the individual level, by
reducing discrimination against PWID, and the policy
level, by enabling a more evidence-based discussion
about harm reduction strategies.
These results should be interpreted in light of several
limitations. First, given that our sample was recruited
online and the majority of participants were politically
liberal, Caucasian adults, the generalizability of our data
are limited. Second, our design is correlational, so it is
not clear to what extent stigma predicts policy support
or vice versa. Third, it would have been helpful to assess
prior exposure to SIFs and NSPs, as well as personal his-
tory of substance use and/or of significant others’ history
of substance use. These variables have been shown to be
important predictors of public stigma, as well as support
toward harm reduction for PWID [13, 28]. Fourth, the
‘double-barreled’ nature of the two policy items in our
study (e.g., referencing both the transmission of HIV and
discouraging the use of illegal drugs in the same item)
can make interpretation of the observed support difficult.
Hence, it is important that future studies include separate
measures of support for NSPs to reduce HIV transmission
and support for NSPs to discourage drug use. Finally, by
adding the qualifier: “if it can be shown…” when connecting
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dressed one of the gaps in the extant literature noted
by Vernick and colleagues [40]. However, it is not clear
how this addition influenced reported support, and
raises questions about people’s knowledge about and
valuing of scientific evidence to guide these policy
decisions.
Conclusion
Despite these limitations, the current study makes a
number of novel contributions to the literature, including
providing the first evaluation of U.S. support for SIFs.
Results indicated the majority of participants support
allocating government resources to fund harm reduction
programs among PWID, and saw PWID as needing help
rather than punishment. Further, beliefs that PWID
deserve punishment, and are potentially dangerous
and need to be avoided are strongly associated with
less endorsement of harm reduction. Considering
whether modifying these beliefs would shift support
for harm reduction strategies will be an important
next step, given the enormous personal and societal
costs of injection drug use.
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